Citadel Advisors
OCUL icon

Citadel Advisors’s Ocular Therapeutix OCUL Stock Holding History

Citadel Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.38M Buy
398,800
+49,000
+14% +$467K ﹤0.01% 5024
2025
Q4 		$4.25M Buy
349,800
+142,300
+69% +$1.73M ﹤0.01% 4543
2025
Q3 		$2.43M Buy
207,500
+79,600
+62% +$952K ﹤0.01% 5674
2025
Q2 		$1.19M Sell
127,900
-12,000
-9% -$93.9K ﹤0.01% 6714
2025
Q1 		$1.03M Buy
139,900
+24,800
+22% +$191K ﹤0.01% 6902
2024
Q4 		$983K Buy
115,100
+76,000
+194% +$741K ﹤0.01% 7060
2024
Q3 		$340K Buy
39,100
+26,000
+198% +$214K ﹤0.01% 9058
2024
Q2 		$89.6K Sell
13,100
-20,800
-61% -$128K ﹤0.01% 11069
2024
Q1 		$308K Sell
33,900
-9,200
-21% -$65.3K ﹤0.01% 9395
2023
Q4 		$192K Sell
43,100
-800
-2% -$2.37K ﹤0.01% 10017
2023
Q3 		$138K Sell
43,900
-45,800
-51% -$187K ﹤0.01% 10481
2023
Q2 		$463K Sell
89,700
-240,000
-73% -$1.43M ﹤0.01% 8117
2023
Q1 		$1.74M Buy
329,700
+257,600
+357% +$1.22M ﹤0.01% 5649
2022
Q4 		$203K Buy
72,100
+2,800
+4% +$9.27K ﹤0.01% 10111
2022
Q3 		$288K Buy
69,300
+56,400
+437% +$284K ﹤0.01% 9670
2022
Q2 		$52K Sell
12,900
-14,400
-53% -$54.4K ﹤0.01% 11918
2022
Q1 		$135K Sell
27,300
-82,100
-75% -$455K ﹤0.01% 11971
2021
Q4 		$763K Sell
109,400
-160,800
-60% -$1.25M ﹤0.01% 8607
2021
Q3 		$2.7M Buy
270,200
+79,200
+41% +$889K ﹤0.01% 5608
2021
Q2 		$2.71M Buy
191,000
+151,300
+381% +$2.3M ﹤0.01% 5862
2021
Q1 		$651K Buy
39,700
+8,900
+29% +$171K ﹤0.01% 9110
2020
Q4 		$638K Buy
30,800
+5,700
+23% +$84.7K ﹤0.01% 7687
2020
Q3 		$191K Sell
25,100
-13,400
-35% -$111K ﹤0.01% 8845
2020
Q2 		$321K Buy
38,500
+4,900
+15% +$32.5K ﹤0.01% 7810
2020
Q1 		$166K Buy
33,600
+20,000
+147% +$98.7K ﹤0.01% 8194
2019
Q4 		$54K Sell
13,600
-10,600
-44% -$36.9K ﹤0.01% 8733
2019
Q3 		$74K Sell
24,200
-100
-0.4% -$447 ﹤0.01% 8602
2019
Q2 		$107K Sell
24,300
-7,000
-22% -$25.9K ﹤0.01% 8513
2019
Q1 		$124K Buy
+31,300
New +$126K ﹤0.01% 8470
2018
Q4 		– Sell
-36,600
Closed -$252K – 9579
2018
Q3 		$252K Buy
36,600
+13,800
+61% +$86.6K ﹤0.01% 7861
2018
Q2 		$154K Buy
22,800
+3,000
+15% +$20.6K ﹤0.01% 8049
2018
Q1 		$129K Buy
19,800
+8,900
+82% +$50.1K ﹤0.01% 7614
2017
Q4 		$49K Sell
10,900
-13,800
-56% -$70.5K ﹤0.01% 7639
2017
Q3 		$153K Sell
24,700
-17,000
-41% -$109K ﹤0.01% 6843
2017
Q2 		$387K Buy
41,700
+18,200
+77% +$176K ﹤0.01% 5500
2017
Q1 		$218K Buy
23,500
+3,300
+16% +$27.5K ﹤0.01% 6375
2016
Q4 		$169K Buy
+20,200
New +$157K ﹤0.01% 6421
2016
Q2 		– Sell
-13,400
Closed -$129K – 7219
2016
Q1 		$129K Buy
13,400
+12,500
+1,389% +$94.7K ﹤0.01% 5908
2015
Q4 		$8K Buy
+900
New +$9.72K ﹤0.01% 8342

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors's OCUL Position: Q1 2026 in Review

Citadel Advisors reduced its Ocular Therapeutix (OCUL) stake by 74% in Q1 2026, selling an estimated $17.5M and leaving 635,922 shares worth $5.39M. The position accounts for ﹤0.01% of the portfolio, ranked #4230.

Citadel Advisors first reported a position in OCUL in Q2 2015 and has held it in 36 quarters since. The position peaked at $66.7M in Q3 2025. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • Citadel Advisors held 635,922 shares of Ocular Therapeutix worth $5.39M as of Q1 2026.
  • Citadel Advisors sold 1,839,927 Ocular Therapeutix shares in Q1 2026, an estimated $17.5M.
  • Ocular Therapeutix made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4230 holding.
  • Citadel Advisors first reported a position in Ocular Therapeutix in Q2 2015 and has held it in 36 quarters since.
  • Citadel Advisors's Ocular Therapeutix position peaked at $66.7M in Q3 2025.
  • 269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.